EDP 305

Drug Profile

EDP 305

Alternative Names: EDP 305

Latest Information Update: 12 Jan 2017

Price : $50

At a glance

  • Originator Enanta Pharmaceuticals
  • Class Small molecules
  • Mechanism of Action Farnesoid X-activated receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    Non-alcoholic fatty liver disease
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Non-alcoholic fatty liver disease
  • Preclinical Non-alcoholic steatohepatitis; Primary biliary cirrhosis

Most Recent Events

  • 06 Jan 2017 Pharmacodynamics data from preclinical studies in Non-alcoholic steatohepatitis released by Enanta Pharmaceuticals
  • 06 Jan 2017 Enanta plans phase II trial for Non-alcoholic steatohepatitis and Cholangitis
  • 04 Jan 2017 EDP 305 receives Fast Track designation for Non-alcoholic fatty liver disease [PO,Suspension] in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top